Psyence Biomedical Ltd (PBM)

$7.91 -1.12 (-12.40%)
Market Cap 9.23M
Revenue (ttm) 0.00
Net Income (ttm) 1.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,385,200
Avg Vol 3,210,428
Day's Range N/A - N/A
Shares Out 1.02M
Stochastic %K 37%
Beta 0.31
Analysts Strong Buy
Price Target N/A

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 346 7764
Address:
121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada
ChartChartist
ChartChartist Apr. 25 at 4:35 PM
$NWGL ngl nwgl The play is nwgl lets see it go $PBM about that life $ZONE ready again $MGN i can do it
0 · Reply
ProfProfit
ProfProfit Apr. 25 at 3:30 PM
$PBM I got in at $11, averaged down at $8 to a $9.75 aberage and am absolutely kickin myself for not getting out at even yesterday. I dont like this set up at all. I saw that bear flag forming and didnt sell. I hope I’m wrong, but unfortunately I believe it goes below 7 and may not go above 9 again for a while, if ever
0 · Reply
SwingTradezzz
SwingTradezzz Apr. 25 at 2:55 PM
$PBM One year ago 60 minutes did a deep dive on the benefits of Psychadelics and Ibogaine. The results were immaculate. One year later, Trump begins trials. Trump is the most controversial President of our time, but the leaps he makes for our country are undeniable. Imagine once trials are approved the scalability of these products. The healing that will take place. The secondary impact it can make on the economy and all of the veterans, addicts, and people that struggle with mental health becoming better productive members of society. Better than they have ever been. That will be the impact of this legislation. Only the people that have not experienced Psychadelics will call this crazy. This is real, and to be honest this video really doesn’t capture the immense healing powers of the drug. It’s hard to put into words how it actually affects your psyche. https://youtu.be/_zpe_G8_k1s?si=5ztvKHmZI7V40Oi_
1 · Reply
Jumpmanz
Jumpmanz Apr. 25 at 3:36 AM
$CMPS $DFTX $ENVB $GHRS $PBM
0 · Reply
ProfProfit
ProfProfit Apr. 25 at 1:17 AM
$PBM what the hell was the PM high on this today?
0 · Reply
History101
History101 Apr. 25 at 1:16 AM
$ENVB $CMPS $GHRS $DFTX $PBM bullish article https://www.zerohedge.com/markets/fda-grants-quick-review-psychedelic-drugs-first-approvals-could-come-soon-summer
0 · Reply
SwingTradezzz
SwingTradezzz Apr. 24 at 10:41 PM
$TORO THERE SHE GOES!!! BULLISH! $PBM $SKLZ lets goooo
0 · Reply
Jockne40
Jockne40 Apr. 24 at 9:47 PM
$PBM perfect flag formation formed
1 · Reply
whyareyou
whyareyou Apr. 24 at 9:47 PM
$PBM the mushrooms gods have spoken… doubling my position in time for the weekend 🍄
1 · Reply
whyareyou
whyareyou Apr. 24 at 9:38 PM
$PBM every setback is the setup for a get back… buy buy buy
1 · Reply
Latest News on PBM
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Apr 23, 2026, 7:00 AM EDT - 2 days ago

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Apr 20, 2026, 10:33 AM EDT - 5 days ago

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Apr 20, 2026, 7:42 AM EDT - 5 days ago

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Apr 17, 2026, 9:15 AM EDT - 8 days ago

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Apr 8, 2026, 9:15 AM EDT - 17 days ago

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

Mar 11, 2026, 9:15 AM EDT - 6 weeks ago

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Mar 3, 2026, 9:15 AM EST - 7 weeks ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Feb 20, 2026, 5:20 PM EST - 2 months ago

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Feb 17, 2026, 9:15 AM EST - 2 months ago

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Feb 13, 2026, 6:30 PM EST - 2 months ago

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Psyence BioMed Announces Settlement of Shareholder Litigation

Feb 11, 2026, 9:15 AM EST - 2 months ago

Psyence BioMed Announces Settlement of Shareholder Litigation

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Jan 28, 2026, 6:30 PM EST - 3 months ago

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Jan 22, 2026, 1:42 PM EST - 3 months ago

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Jan 20, 2026, 7:19 AM EST - 3 months ago

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Jan 12, 2026, 8:30 AM EST - 3 months ago

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Jan 5, 2026, 9:15 AM EST - 3 months ago

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Dec 19, 2025, 7:00 AM EST - 4 months ago

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Dec 9, 2025, 7:00 AM EST - 4 months ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 25, 2025, 7:00 AM EST - 5 months ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 20, 2025, 7:00 AM EST - 5 months ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 12, 2025, 7:00 AM EST - 5 months ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 6, 2025, 7:00 AM EST - 6 months ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Nov 3, 2025, 7:00 AM EST - 6 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Aug 28, 2025, 8:00 AM EDT - 8 months ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jul 31, 2025, 7:30 AM EDT - 9 months ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 25, 2025, 5:00 PM EDT - 10 months ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 11 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 18, 2025, 8:30 AM EDT - 11 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

Jun 17, 2025, 8:00 AM EDT - 11 months ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 27, 2025, 7:30 AM EDT - 11 months ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

May 1, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 7:17 PM EDT - 1 year ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Group Announces Share Consolidation

Apr 17, 2025, 9:39 AM EDT - 1 year ago

Psyence Group Announces Share Consolidation

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Mar 10, 2025, 11:18 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 1 year ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 25, 2024, 9:42 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

ChartChartist
ChartChartist Apr. 25 at 4:35 PM
$NWGL ngl nwgl The play is nwgl lets see it go $PBM about that life $ZONE ready again $MGN i can do it
0 · Reply
ProfProfit
ProfProfit Apr. 25 at 3:30 PM
$PBM I got in at $11, averaged down at $8 to a $9.75 aberage and am absolutely kickin myself for not getting out at even yesterday. I dont like this set up at all. I saw that bear flag forming and didnt sell. I hope I’m wrong, but unfortunately I believe it goes below 7 and may not go above 9 again for a while, if ever
0 · Reply
SwingTradezzz
SwingTradezzz Apr. 25 at 2:55 PM
$PBM One year ago 60 minutes did a deep dive on the benefits of Psychadelics and Ibogaine. The results were immaculate. One year later, Trump begins trials. Trump is the most controversial President of our time, but the leaps he makes for our country are undeniable. Imagine once trials are approved the scalability of these products. The healing that will take place. The secondary impact it can make on the economy and all of the veterans, addicts, and people that struggle with mental health becoming better productive members of society. Better than they have ever been. That will be the impact of this legislation. Only the people that have not experienced Psychadelics will call this crazy. This is real, and to be honest this video really doesn’t capture the immense healing powers of the drug. It’s hard to put into words how it actually affects your psyche. https://youtu.be/_zpe_G8_k1s?si=5ztvKHmZI7V40Oi_
1 · Reply
Jumpmanz
Jumpmanz Apr. 25 at 3:36 AM
$CMPS $DFTX $ENVB $GHRS $PBM
0 · Reply
ProfProfit
ProfProfit Apr. 25 at 1:17 AM
$PBM what the hell was the PM high on this today?
0 · Reply
History101
History101 Apr. 25 at 1:16 AM
$ENVB $CMPS $GHRS $DFTX $PBM bullish article https://www.zerohedge.com/markets/fda-grants-quick-review-psychedelic-drugs-first-approvals-could-come-soon-summer
0 · Reply
SwingTradezzz
SwingTradezzz Apr. 24 at 10:41 PM
$TORO THERE SHE GOES!!! BULLISH! $PBM $SKLZ lets goooo
0 · Reply
Jockne40
Jockne40 Apr. 24 at 9:47 PM
$PBM perfect flag formation formed
1 · Reply
whyareyou
whyareyou Apr. 24 at 9:47 PM
$PBM the mushrooms gods have spoken… doubling my position in time for the weekend 🍄
1 · Reply
whyareyou
whyareyou Apr. 24 at 9:38 PM
$PBM every setback is the setup for a get back… buy buy buy
1 · Reply
RoyalImperial
RoyalImperial Apr. 24 at 9:22 PM
MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $AUUD $ENVB $PBM $QS /
0 · Reply
Tradebub
Tradebub Apr. 24 at 9:17 PM
$PBM and $ENVB No love for the magic shrooms.
1 · Reply
ProfessorDman1
ProfessorDman1 Apr. 24 at 8:41 PM
$AKAN $ENVB $LRHC $PBM $SKLZ ( LRHC let’s see $5+ atleast it has all the potential and ingredients going into Monday )
0 · Reply
shock89
shock89 Apr. 24 at 8:20 PM
$AKAN $ENVB $LRHC $PBM $SKLZ
0 · Reply
SETRADING126
SETRADING126 Apr. 24 at 7:59 PM
$PBM ADDING!! 😃👏🥳🎉 1.28 MIL VOL
0 · Reply
crowbarisfat
crowbarisfat Apr. 24 at 7:43 PM
$PBM bought before executive order... sold on monday at 15😭 First year investing it really is simpler than all yall make it out to be.
2 · Reply
SonOfSea
SonOfSea Apr. 24 at 7:43 PM
$PBM bought it for $10+ still holding, not sure it's make sense.
0 · Reply
Wildblitz
Wildblitz Apr. 24 at 7:20 PM
$PBM took a loss on this trash
1 · Reply
Zero11
Zero11 Apr. 24 at 7:04 PM
$PBM exactly, last chance to add if anything
1 · Reply
whyareyou
whyareyou Apr. 24 at 7:03 PM
$PBM everyone crying and shitting the bed 😂😂 patience
0 · Reply
ReaLiLJ
ReaLiLJ Apr. 24 at 6:52 PM
$AKAN $ENVB $LRHC $PBM $SKLZ
0 · Reply
ProfessorDman1
ProfessorDman1 Apr. 24 at 6:50 PM
$ENVB nice one today Yesterday $SKLZ $PBM and $AKAN both idea ran 500%+ I’m liking $LRHC could do single shot boom to $10+ like rest of them
0 · Reply